tavaborole

Therapeutic Classification: antifungals

Pharmacologic Classification: oxaboroles

Indications ⬆ ⬇

REMS

Toenail onychomycosis.

Action ⬆ ⬇

Inhibits fungal protein synthesis via inhibition of aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS).

Therapeutic effects:

Resolution of toenail fungus.

Spectrum:

Active against Trychophyton rubrum and Trychophyton mentagrophytes.

Pharmacokinetics ⬆ ⬇

Absorption: Minimal absorption follows topical administration.

Distribution: Unknown.

Metabolism/Excretion: Extensively metabolized, metabolites are eliminated mostly in urine.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

(resolution of infection)

ROUTE	ONSET	PEAK	DURATION
Top	unknown	unknown	48 wk‡

‡Length of treatment necessary for resolution of infection.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

None noted.

Use Cautiously in:

OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
Pedi: Children 6 yr (safety and effectiveness not established);
Geri: Older adults may be more sensitive to drug effects.

Adv. Reactions/Side Effects ⬆ ⬇

Local: dermatitis, erythema, exfoliation, ingrown toenail

Interactions ⬆ ⬇

Drug-drug:

None noted.

Route/Dosage ⬆ ⬇

(Adults and Children ≥6 yr): Apply to affected nail once daily for 48 wk.

Availability ⬆ ⬇

Topical solution: 5%

Assessment ⬆ ⬇

Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Implementation ⬆ ⬇

Apply daily for 48 wks to clean, dry toenail surface and under tip of toenail. Avoid contact with skin other than skin immediately surrounding treated nail. Wipe excess solution away from surrounding skin. Allow solution to dry following application. Avoid contact with eyes or mucous membranes. Solution is clear and colorless.

Patient/Family Teaching ⬆ ⬇

Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes. Caution patient that solution is flammable; avoid use near heat or open flame. Discard bottle 3 mo after inserting dropper. Advise patient to read Patient Information sheet prior to starting therapy and with each Rx refill in case of changes.
Advise patient to notify health care professional if area of application shows signs of persistent irritation (redness, itching, swelling, skin peeling, ingrown toenail).
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes ⬆ ⬇

Resolution of toenail fungus.

US Brand Names ⬆ ⬇

Pot. Nursing Diagnoses ⬆ ⬇

Risk for impaired skin integrity(Indications)
Risk for infection(Indications)

Code ⬆

NDC Code

10337- PharmaDerm, A division of Fougera Pharmaceuticals Inc.
- 10337-905- Kerydin
  - 10337-905-10- 1 BOTTLE, WITH APPLICATOR in 1 CARTON (10337-905-10) > 10 mL in 1 BOTTLE, WITH APPLICATOR

10337- PharmaDerm, A division of Fougera Pharmaceuticals Inc.
- 10337-905- Kerydin
  - 10337-905-44- 1 BOTTLE, WITH APPLICATOR in 1 CARTON (10337-905-44) > 4 mL in 1 BOTTLE, WITH APPLICATOR

section name header

Pronunciation ⬇

Classifications ⬆ ⬇